Uniferon U.S. Anemia Summit in Denmark

September 14, 2016

Pharmacosmos hosted its first ever U.S. Uniferon® Iron Deficiency Anaemia Summit Conference from August 17-19, 2016 at Holbaek, Denmark.  Attending the event was a highly qualified and distinguished group of U.S swine veterinrians and representatives from our Uniferon® distribution partners in the U.S veterinary market.

A variety of topics were covered during the meeting, all of which led to impactful dialogue between U.S. attendees and Danish swine experts.  While visiting a Danish sow farm, participants engaged in open and candid discussions with the farm manager, the employees and a swine veterinarian.  Many ideas and differences between Danish and U.S. pig production and management procedures were shared among the participants, with numerous best-practices taken away by all. The sow-farm visit allowed the group to participate in a practical, on-site iron deficiency anaemia investigation in which a comprehensive evaluation of iron injection techniques were presented; secondary iron dosages were discussed and determined; and the prevalence of sub-clinical and full-scale iron deficiencey anaemia observations  in a production environment were made using pen-side hemoglobin blood level determinations.

The hands-on session was followed by an in-depth review of the causes and consequences of sub-clinical and full-scale iron deficiency anaemia in piglets from a theoretical perspective.  Professor Jens Peter Nielsen from the University of Copenhagen, provided an update on research, which indicates there is solid scientific evidence that a boost in hemoglobin to optimal  blood levels increases average daily gain in piglets from farrowing to finishing.  Optimal blood levels of hemoglobin can be achieved in piglets on an all-milk diet with the use of a second injection of Uniferon® iron dextran. As part of the sub-clinical and full-scale iron defficiency anaemia  conversation, a tour of the Pharmacosmos manufacturing facility was conducted, whereby participants learned that the Uniferon® injectable iron products are unique in that Pharmacosmos applies the same high-quality standards to the production of its veterinary iron as it does to the production of  its human iron products, while strictly avoiding the use of organic solvents and cyanide in the manufacture and processing thereof.  In short, there are simply no potentially harmful residual organic solvents or cyanide impurities to be found in, or dealt with in the usage of Uniferon® injectable iron products!

Other topics covered during the meeting included the Danish pig production experience with reduced antibiotic usage, and increased weaning age of the piglets.  Both topics were accompanied by productive discussions among the group regarding the challenges and potential benefits such changes could bring to U.S. swine production.  The candid  discussions of the group proved to be a valuable benefit to the meeting as attendees and local experts had an opportinity to learn from each others experiences on all topics discussed during the Uniferon® Iron Deficiency Anaemia Summit Conference.

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.